151 related articles for article (PubMed ID: 197026)
21. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
Gerber P; Ablashi D; Magrath I; Armstrong G; Andersen P; Trach L
J Natl Cancer Inst; 1982 Sep; 69(3):585-90. PubMed ID: 6287082
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effect of 1-beta-D-arabinofuranosylthymine on synthesis of Epstein-Barr virus.
Yonemura K; Sairenji T; Hinuma Y
Microbiol Immunol; 1981; 25(6):557-63. PubMed ID: 6268944
[TBL] [Abstract][Full Text] [Related]
23. [Suppressive effect of CDDP on induction of the Epstein-Barr virus antigen synthesis by n-butyrate].
Furukawa M; Kato C; Kamide M; Umeda R
Nihon Jibiinkoka Gakkai Kaiho; 1989 Feb; 92(2):189-93. PubMed ID: 2545850
[TBL] [Abstract][Full Text] [Related]
24. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D
Intervirology; 1975; 5(6):319-34. PubMed ID: 181343
[TBL] [Abstract][Full Text] [Related]
25. Multiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV.
Cho MS; Fresen KO; zur Hausen H
Int J Cancer; 1980 Sep; 26(3):357-63. PubMed ID: 6270006
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells.
Qualtiere LF; Pearson GR
Int J Cancer; 1979 Jun; 23(6):808-17. PubMed ID: 89099
[TBL] [Abstract][Full Text] [Related]
27. Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle.
Klein G; Clements G; Zeuthen J; Westman A
Int J Cancer; 1976 Jun; 17(6):715-24. PubMed ID: 59708
[TBL] [Abstract][Full Text] [Related]
28. Combined effect of the extracts from Croton tiglium, Euphorbia lathyris or Euphorbia tirucalli and n-butyrate on Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells.
Ito Y; Kawanishi M; Harayama T; Takabayashi S
Cancer Lett; 1981 Apr; 12(3):175-80. PubMed ID: 6266651
[TBL] [Abstract][Full Text] [Related]
29. [Studies on the synthesis of Epstein-Barr virus-related antigens induced by superinfection].
Fujiwara S
Hokkaido Igaku Zasshi; 1984 Sep; 59(5):586-602. PubMed ID: 6096242
[TBL] [Abstract][Full Text] [Related]
30. Suppression of Epstein-Barr virus reactivation in lymphoblastoid cells cultured in simulated microgravity.
Long JP; Pierson S; Hughes JH
In Vitro Cell Dev Biol Anim; 1999 Jan; 35(1):49-54. PubMed ID: 10475255
[TBL] [Abstract][Full Text] [Related]
31. Effect of nickel sulfate on cellular proliferation and Epstein-Barr virus antigen expression in lymphoblastoid cell lines.
Wu YT; Luo HL; Johnson DR
Cancer Lett; 1986 Aug; 32(2):171-9. PubMed ID: 3019516
[TBL] [Abstract][Full Text] [Related]
32. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Fresen KO; zur Hausen H
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
[TBL] [Abstract][Full Text] [Related]
33. Effect of adenine arabinoside on Epstein-Barr virus in vitro.
Coker-Vann M; Dolin R
J Infect Dis; 1977 Mar; 135(3):447-53. PubMed ID: 191542
[TBL] [Abstract][Full Text] [Related]
34. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
Kurakata S; Ramos OF; Klein G; Klein E
Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147
[TBL] [Abstract][Full Text] [Related]
35. A novel early antigen associated with Epstein-Barr virus productive cycle.
Freemer CS; Bertoni G; Takagi S; Sairenji T
Virology; 1993 May; 194(1):387-92. PubMed ID: 8386883
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus (EBV)--lymphoid cell interactions. II. The influence of the EBV replication cycle on natural killing and antibody-dependent cellular cytotoxicity against EBV-infected cells.
Patel PC; Menezes J
Clin Exp Immunol; 1982 Jun; 48(3):589-601. PubMed ID: 6288292
[TBL] [Abstract][Full Text] [Related]
37. Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.
Alfieri C; Ghibu F; Joncas JH
Can Med Assoc J; 1984 Nov; 131(10):1249-52. PubMed ID: 6093976
[TBL] [Abstract][Full Text] [Related]
38. Complementation between infecting Epstein-Barr virus and intrinsic viral genomes in human lymphoid cell lines.
Lidin BI; Lamon EW; Cloud G; Soong SJ
Intervirology; 1982; 18(1-2):66-75. PubMed ID: 6288617
[TBL] [Abstract][Full Text] [Related]
39. Differential inhibition of Epstein-Barr virus induction by the amino acid analogue, L-canavanine.
Yamamoto N; Mueller-Lantzsch N; zur Hausen H
Int J Cancer; 1980 Apr; 25(4):439-43. PubMed ID: 6246007
[TBL] [Abstract][Full Text] [Related]
40. The interaction of non-transforming Epstein-Barr virus (EBV) with cell-associated EBV DNA in superinfected lymphoblastoid cell lines.
Stoerker J; Yajima Y; Glaser R
Int J Cancer; 1982 Oct; 30(4):385-92. PubMed ID: 6292115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
